Gain Therapeutics, Inc. Common Stock (GANX) is a publicly traded Healthcare sector company. As of May 21, 2026, GANX trades at $1.65 with a market cap of $69.10M and a P/E ratio of -2.70. GANX moved +4.09% today. Year to date, GANX is -44.44%; over the trailing twelve months it is -13.61%. Its 52-week range spans $1.41 to $4.34. Analyst consensus is strong buy with an average price target of $7.20. Rallies surfaces GANX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
5 analysts cover GANX: 0 strong buy, 5 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $7.20.
| Metric | Value |
|---|---|
| Price | $1.65 |
| Market Cap | $69.10M |
| P/E Ratio | -2.70 |
| EPS | $-0.61 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.34 |
| 52-Week Low | $1.41 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-20.16M |
| Gross Margin | 0.00% |
5 analysts cover GANX: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.20.